DDReg Pharma- Consulting in regulatory affairs and drug safety

One of the most basic differences in veterinary risk assessment is that safety must be assessed in more than one species. Unlike human pharmaceuticals, which are typically developed to operate within the confines of a single species, Veterinary drug developers must establish safety profiles across a wide range of species.     Designing a drug to be safe for dogs, cats, horses, and cattle all at once is like developing a drug that works safely for species as physiologically distinct as cats, cattle, and poultry. Pharmacokinetic profiles may vary significantly between species, necessitating species-specific dosing and safety evaluations. Likewise, dosage calculations become exponentially more challenging when treating an animal that can vary in weight from a small cat to a horse. These include notably different rates of metabolism, organ functions, and natural detoxification processes between species, making toxicity assessments difficult.   The Environmental Impact Factor ...

  Biosimilars are biologic products highly similar to an already approved reference product, with no clinically meaningful differences in safety, purity, or potency. Unlike generic drugs, biosimilars involve intricate manufacturing processes due to the complexity of their molecular structures and the living systems used in their production. Given their potential to reduce healthcare costs and increase patient access, regulatory authorities in the EU and US have established specific pathways to ensure the safety, efficacy, and quality of these products. Read more about different pathways here:  https://resource.ddregpharma.com/blogs/a-complete-guide-to-regulatory-pathways-for-biosimilars-in-the-eu-and-us/ Contact us today to fastrack your product in the market:  https://resource.ddregpharma.com/blogs/a-complete-guide-to-regulatory-pathways-for-biosimilars-in-the-eu-and-us/

South Korea has a structured system for classifying pharmaceuticals, determining regulatory requirements and approval pathways. This classification system categorizes pharmaceutical products and their ingredients; further, these drug products can be divided into three categories. Firstly, new drugs, as defined by unique chemical structures or original composition, require extensive clinical and non-clinical data in order to demonstrate safety and efficacy. Second, Certain pharmaceuticals with improved efficacy or novel active ingredient compositions require additional data submission. Thirdly, generics, which are bioequivalents of reference drugs. Their classification system serves as a framework that determines which level of documentation and tests will be needed in order to obtain regulatory approval.  Read more:   https://resource.ddregpharma.com/blogs/navigating-the-drug-regulatory-landscape-of-south-korea/